APYX

Apyx Medical's stock has experienced significant events driven by financial performance and product developments. As of May 1, 2026, the share price was $3.06, a 166.09% increase from May 5, 2025. In Q4 2025, Apyx Medical reported record revenue of $19.2 million, with full-year revenue at $52.8 million, driven by the AYON Body Contouring System launch. The company narrowed its net loss to $11.2 million for 2025 and provided a revenue forecast for 2026. In Q1 2026, revenue was $12.5 million, a 32% increase, driven by the Surgical Aesthetics segment, and the net loss narrowed. Apyx Medical raised its FY2026 revenue guidance, and the stock price increased after the Q1 2026 earnings announcement. The anticipated FDA clearance for AYON power liposuction is a future growth catalyst.